Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market: Powering Innovation and Expansion in the Ischemic Heart Disease (IHD) Drugs Market by 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Is the Expected CAGR for the Ischemic Heart Disease (IHD) Drugs Market Through 2025?
The market for ischemic heart disease (IHD) medications has seen substantial growth in the past few years. The market is predicted to expand from $6.36 billion in 2024 to $6.71 billion in 2025, showcasing a compound annual growth rate (CAGR) of 5.6%. Several factors contributed to the growth experienced in the previous period. These include the rising worldwide incidence of ischemic heart disease, improved consciousness and diagnostic methods, alterations in lifestyle and diet, government efforts to promote cardiovascular health, partnerships for clinical trials, as well as insurance coverage and reimbursement policies.

What's the Projected Size of the Global Ischemic Heart Disease (IHD) Drugs Market by 2029?
The market for ischemic heart disease (IHD) drugs is predicted to witness consistent expansion in the coming years, reaching an estimated value of $7.86 billion in 2029, with a compound annual growth rate (CAGR) of 4.0%. This projected growth during the forecast period is attributed to factors such as an ageing population, the use of individualized medical plans, cardiovascular prevention strategies, worldwide health policies and initiatives, and global research partnerships. Notable trends that should be seen during this forecast period include a shift toward precision medical methods, emphasis on newer anti-atherogenic agents, advancements in methods of lowering lipid levels, the incorporation of anti-inflammatory agents, and the production of anti-clotting and antiplatelet drugs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Top Growth Drivers in the Ischemic Heart Disease (IHD) Drugs Industry: What's Accelerating the Market?
The rise in obesity and diabetes cases is anticipated to facilitate the expansion of the ischemic heart disease (IHD) drugs market. Diabetes is a long-standing disorder associated with high blood glucose concentrations while obesity is hallmarked by extreme body fat accumulation, damaging health. Ischemic heart disease drugs are frequently employed for individuals suffering from obesity and diabetes to control cardiovascular risk contributors like hypertension and dyslipidemia, hence lessening the likelihood of ischemic heart disease. For example, the World Obesity Federation predicts that by 2030, one billion people globally, including 1 in 5 women and 1 in 7 men, will be obese. Furthermore, the National Health Service in the UK stated that in 2023, over half a million (549,000) more individuals in England were identified as being at risk of type 2 diabetes, raising the total number of prediabetic people registered with a GP to 3,615,330, a near 20% increase from 3,065,825 in 2022. Thus, the escalating prevalence of obesity and diabetes fuels the growth of the ischemic heart disease (IHD) drugs market. A surge in heart failure incidents is projected to catalyze the growth of the ischemic heart disease (IHD) drug market. Heart failure is a long-term condition where the heart's ability to adequately pump blood to meet the body's necessity for blood and oxygen is compromised. Symptoms can include fatigue, breathlessness and difficulty in carrying out daily tasks. Ischemic heart disease (IHD) drugs are critical in managing heart failure, helping avert its occurrence by reducing risk factors and symptoms of ischemic heart disease. These medications inhibit the pacemaker activity of the heart and are beneficial for heart failure patients with low ejection fractions and high resting heart rates post a tolerated beta-blocker. The Heart Failure Society of America reports that as of September 2023, heart failure (HF) affects 6.7 million Americans over the age of 20, a number expected to increase to 8.5 million by 2030. Therefore, this rise in heart failure cases propels the growth of the ischemic heart disease (IHD) drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

What Trends Will Shape the Ischemic Heart Disease (IHD) Drugs Market Through 2029 and Beyond?
Leading firms in the ischemic heart disease (IHD) drugs market are intensifying their efforts to develop innovative myosin inhibitors, intending to secure a competitive advantage. A cardiac myosin inhibitor is a medication that curbs myosin activity in cardiac muscles, thereby reducing the contracting force. This is beneficial particularly for health conditions such as hypertrophic cardiomyopathy (HCM) that involve excessive muscle thickening that hinders heart functionality. For example, in April 2022, Bristol Myers Squibb, a pharmaceutical company based in the US, introduced Camzyos (mavacamten). This medication is the first-ever cardiac myosin inhibitor endorsed for treating adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM) to ameliorate functional capacity and symptoms. The medication operates as an allosteric and reversible inhibitor selective for cardiac myosin, diminishing hypercontractility, left ventricular hypertrophy, and enhancing cardiac filling pressures. This aids in mitigating dynamic left ventricular outflow tract (LVOT) obstruction.

What Are the Main Segments in the Ischemic Heart Disease (IHD) Drugs Market?
The ischemic heart disease (IHD) drugs market covered in this report is segmented -

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Which Top Companies are Driving Growth in the Ischemic Heart Disease (IHD) Drugs Market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Which Regions Will Dominate the Ischemic Heart Disease (IHD) Drugs Market Through 2029?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.